Berberine attenuates hepatic oxidative stress in rats with non‑alcoholic fatty liver disease via the Nrf2/ARE signalling pathway

Deng,Yuanjun; Tang,Kairui; Chen,Runsen; Nie,Huan; Liang,Shu; Zhang,Jinwen; Zhang,Yupei; Yang,Qinhe

doi:10.3892/etm.2019.7208

Berberine attenuates hepatic oxidative stress in rats with non‑alcoholic fatty liver disease via the Nrf2/ARE signalling pathway

Authors:
- Yuanjun Deng
- Kairui Tang
- Runsen Chen
- Huan Nie
- Shu Liang
- Jinwen Zhang
- Yupei Zhang
- Qinhe Yang
View Affiliations

Affiliations: School of Traditional Chinese Medicine, Jinan University, Guangzhou, Guangdong 510632, P.R. China
Published online on: January 28, 2019 https://doi.org/10.3892/etm.2019.7208
Pages: 2091-2098
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the effects of berberine (BBR) on hepatic oxidative stress and the nuclear factor erythroid 2‑related factor 2/antioxidant response element (Nrf2/ARE) signalling pathway in rats in which non‑alcoholic fatty liver disease (NAFLD) was induced by a high‑fat diet. Rats were randomly divided into three groups: The normal control (NC), high‑fat diet (HFD) and BBR groups. The NC group received a normal diet, while the other two groups were fed a high‑fat diet. The rats in the BBR group were also fed BBR (100 mg/kg body weight) daily. A total of 8 weeks later, serum and liver lipid levels were measured. Hepatic histopathological changes were observed with haematoxylin and eosin and Oil Red O staining. Transmission electron microscopy was performed to observe the ultrastructural changes of the liver. The levels of superoxide dismutase (SOD), glutathione (GSH) and malondialdehyde (MDA) in the liver were measured. Quantitative polymerase chain reaction and western blotting were performed to investigate the expression of genes in the Nrf2/ARE signalling pathway in the liver. Histopathological results demonstrated that rats fed a high‑fat diet for 8 weeks developed NAFLD, characterized by hepatic steatosis. BBR significantly decreased the body weight and liver weight. BBR markedly reduced hepatic steatosis, and the serum and liver lipid levels. Hepatic SOD and GSH levels were increased, while MDA levels were decreased by BBR co‑administered with a high‑fat diet. Additionally, the Nrf2/ARE signalling pathway was revealed to be involved in the protective effect of BBR on rats fed a high‑fat diet. In conclusion, BBR may alleviate hepatic oxidative stress in rats with NAFLD, which may be partly attributed to the activation of the Nrf2/ARE signalling pathway.

View Figures

View References

1	Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ: The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 55:2005–2023. 2012. View Article : Google Scholar : PubMed/NCBI
2	Than NN and Newsome PN: A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 239:192–202. 2015. View Article : Google Scholar : PubMed/NCBI
3	Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 43 (2 Suppl 1):S99–S112. 2006. View Article : Google Scholar : PubMed/NCBI
4	Musso G, Cassader M and Gambino R: Non-alcoholic steatohepatitis: Emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 15:249–274. 2016. View Article : Google Scholar : PubMed/NCBI
5	Videla LA, Rodrigo R, Araya J and Poniachik J: Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med. 12:555–558. 2006. View Article : Google Scholar : PubMed/NCBI
6	Friedman SL, Neuschwander-Tetri BA, Rinella M and Sanyal AJ: Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 24:908–922. 2018. View Article : Google Scholar : PubMed/NCBI
7	Sakaida I and Okita K: The role of oxidative stress in NASH and fatty liver model. Hepatol Res. 33:128–131. 2005. View Article : Google Scholar : PubMed/NCBI
8	Rolo AP, Teodoro JS and Palmeira CM: Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Bio Med. 52:59–69. 2012. View Article : Google Scholar
9	Kaspar JW, Niture SK and Jaiswal AK: Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radical Bio Med. 47:1304–1309. 2009. View Article : Google Scholar
10	Vomhof-DeKrey EE and Picklo MJ Sr: The Nrf2-antioxidant response element pathway: A target for regulating energy metabolism. J Nutr Biochem. 23:1201–1206. 2012. View Article : Google Scholar : PubMed/NCBI
11	Chambel SS, Santos-Goncalves A and Duarte TL: The dual role of Nrf2 in nonalcoholic fatty liver disease: Regulation of antioxidant defenses and hepatic lipid metabolism. Biomed Res Int 2015. 5971342015.
12	Tang W, Jiang YF, Ponnusamy M and Diallo M: Role of Nrf2 in chronic liver disease. World J Gastroentero. 20:13079–13087. 2014. View Article : Google Scholar
13	Bataille AM and Manautou JE: Nrf2: A potential target for new therapeutics in liver disease. Clin Pharmacol Ther. 92:340–348. 2012. View Article : Google Scholar : PubMed/NCBI
14	Yin J, Zhang H and Ye J: Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets. 8:99–111. 2008. View Article : Google Scholar : PubMed/NCBI
15	Wang C, Li J, Lv X, Zhang M, Song Y, Chen L and Liu Y: Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur J Pharmacol. 620:131–137. 2009. View Article : Google Scholar : PubMed/NCBI
16	Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, et al: Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 10:1344–1351. 2004. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Campbell T, Perry B, Beaurepaire C and Qin L: Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism. 60:298–305. 2011. View Article : Google Scholar : PubMed/NCBI
18	Mo C, Wang L, Zhang J, Numazawa S, Tang H, Tang X, Han X, Li J, Yang M, Wang Z, et al: The crosstalk between Nrf2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice. Antioxid Redox Sign. 20:574–588. 2014. View Article : Google Scholar
19	Liu Y, Zhang L, Song H and Ji G: Update on berberine in nonalcoholic Fatty liver disease. Evid Based Complement Alternat Med 2013. 3081342013.
20	Yang J, Ma XJ, Li L, Wang L, Chen YG, Liu J, Luo Y, Zhuang ZJ, Yang WJ, Zang SF and Shi JP: Berberine ameliorates non-alcoholic steatohepatitis in ApoE(−/-) mice. Exp Ther Med. 14:4134–4140. 2017.PubMed/NCBI
21	Yang QH, Hu SP, Zhang YP, Xie WN, Li N, Ji GY, Qiao NL, Lin XF, Chen TY and Liu HT: Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats. Chin J Integr Med. 17:205–211. 2011. View Article : Google Scholar : PubMed/NCBI
22	Wu D, Wen W, Qi CL, Zhao RX, Lü JH, Zhong CY and Chen YY: Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine. 19:712–718. 2012. View Article : Google Scholar : PubMed/NCBI
23	Gomes AP, Duarte FV, Nunes P, Hubbard BP, Teodoro JS, Varela AT, Jones JG, Sinclair DA, Palmeira CM and Rolo AP: Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim Biophys Acta 1822. 185–195. 2012.
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Jensen VS, Hvid H, Damgaard J, Nygaard H, Ingvorsen C, Wulff EM, Lykkesfeldt J and Fledelius C: Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats. Diabetol Metab Syndr. 10:42018. View Article : Google Scholar : PubMed/NCBI
26	Malaguarnera M, Di Rosa M, Nicoletti F and Malaguarnera L: Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl). 87:679–695. 2009. View Article : Google Scholar : PubMed/NCBI
27	Day CP and James OF: Steatohepatitis: A tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. View Article : Google Scholar : PubMed/NCBI
28	Zhu R, Wang Y, Zhang L and Guo Q: Oxidative stress and liver disease. Hepatol Res. 42:741–749. 2012. View Article : Google Scholar : PubMed/NCBI
29	Tanaka Y, Aleksunes LM, Yeager RL, Gyamfi MA, Esterly N, Guo GL and Klaassen CD: NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. J Pharmacol Exp Ther. 325:655–664. 2008. View Article : Google Scholar : PubMed/NCBI
30	Xu W, Shao L, Zhou C, Wang H and Guo J: Upregulation of Nrf2 Expression in Non-Alcoholic Fatty Liver and Steatohepatitis. Hepatogastroenterology. 58:2077–2080. 2011. View Article : Google Scholar : PubMed/NCBI
31	Okada K, Warabi E, Sugimoto H, Horie M, Gotoh N, Tokushige K, Hashimoto E, Utsunomiya H, Takahashi H, Ishii T, et al: Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet. J Gastroenterol. 48:620–632. 2013. View Article : Google Scholar : PubMed/NCBI
32	Meakin PJ, Chowdhry S, Sharma RS, Ashford FB, Walsh SV, McCrimmon RJ, Dinkova-Kostova AT, Dillon JF, Hayes JD and Ashford ML: Susceptibility of Nrf2-Null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol. 34:3305–3320. 2014. View Article : Google Scholar : PubMed/NCBI
33	Li Z, Geng Y, Jiang J and Kong W: Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid-Based Compl Alt 2014. 2892642014.
34	Yin J, Xing H and Ye J: Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 57:712–717. 2008. View Article : Google Scholar : PubMed/NCBI
35	Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D and Gao X: Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res. 51:2504–2515. 2010. View Article : Google Scholar : PubMed/NCBI
36	Zhou J, Zhou S, Tang J, Zhang K, Guang L, Huang Y, Xu Y, Ying Y, Zhang L and Li D: Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur J Pharmacol. 606:262–268. 2009. View Article : Google Scholar : PubMed/NCBI
37	Hsu YY, Chen CS, Wu SN, Jong YJ and Lo YC: Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase/Akt-dependent mechanism in NSC34 motor neuron-like cells. Eur J Pharm Sci. 46:415–425. 2012. View Article : Google Scholar : PubMed/NCBI
38	Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR, et al: Genetic versus chemoprotective activation of Nrf2 signaling: Overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis. 30:1024–1031. 2009. View Article : Google Scholar : PubMed/NCBI